BITT will leverage Selexis’ suite of proprietary modular technologies designed to overcome the complex challenges of protein-expression and deliver the high performance research cell banks necessar...
Acquisition augments CrownBio’s preclinical in vitro service platforms, adding high content imaging and advanced tumor organoid analytics to three-dimensional immuno-oncology drug assays
MBL has begun manufacturing the RUO kit, called FLUOROSEARCH Novel Coronavirus (SARS-CoV-2) Detection Kit, at a capacity of several tens of thousands of tests per month and will begin accepting ord...
Partnership combines breakthrough organoid technology with the world’s largest PDX collection to create a unique patient-derived translational research platform
Continued Collaboration Facilitates Global Distribution of Obesity, Metabolic Disease, and NASH Model and Priority Supply to CrownBio’s World-Class Cardiovascular, Obesity, and Metabolic Disease Pl...
Crown Bioscience announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the d...